Kenvue (NYSE:KVUE) Given New $19.00 Price Target at The Goldman Sachs Group

Kenvue (NYSE:KVUE) had its price objective lowered by The Goldman Sachs Group from $22.00 to $19.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. dropped their price objective on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, July 25th. Zacks Research raised shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. Citigroup restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, September 23rd. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. Finally, Canaccord Genuity Group decreased their target price on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $22.46.

Kenvue Trading Down 0.9%

NYSE KVUE opened at $15.72 on Thursday. The stock has a market capitalization of $30.16 billion, a P/E ratio of 21.24, a P/E/G ratio of 2.28 and a beta of 0.72. Kenvue has a 52-week low of $15.47 and a 52-week high of $25.17. The firm has a 50-day moving average price of $19.85 and a 200 day moving average price of $21.63. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. During the same period last year, the company posted $0.32 earnings per share. The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts expect that Kenvue will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 5.3%. The ex-dividend date of this dividend was Wednesday, August 13th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is presently 112.16%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Pittenger & Anderson Inc. acquired a new position in shares of Kenvue in the 1st quarter valued at about $30,000. TruNorth Capital Management LLC acquired a new position in shares of Kenvue in the 1st quarter valued at about $36,000. Truvestments Capital LLC acquired a new position in shares of Kenvue in the 1st quarter valued at about $37,000. Trust Co. of Vermont boosted its holdings in shares of Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after buying an additional 1,287 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.